CHRONIC MYELOID LEUKEMIA TREATMENT MARKET ANALYSIS

Chronic Myeloid Leukemia Treatment Market, by Drug Type (Tyrosine Kinase Inhibitors (Imatinib (Gleevec), Dasatinib (Sprycel), Nilotinib (Tasigna), Bosutinib (Bosulif), Ponatinib (Iclusig), Asciminib (Scemblix), and Others), Antimetabolites, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Mar 2022
Code : CMI1726
Pages :177
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Restraints & Challenges:

High cost of chronic myeloid leukemia treatment drugs

Global Chronic Myeloid Leukemia Treatment Market: Restraints

Cost is a major factors that influences the selection of treatment. Thus, the high cost of chronic myeloid leukemia treatment drugs is expected to hamper the growth global chronic myeloid treatment market. Furthermore, in an article published by American Society of Clinical Oncology Journal in August 2020, mean annualized costs for CML was US$ 82,054, more than those for hematologic malignancies (HEM) US$ 74,993 in the U.S.

Growth Drivers: